Then yesterday, the FDA’s oncologic drugs advisory committee recommended approval of rituximab in a new subcutaneous formulation in a range of lymphomas and chronic lymphocytic leukemia.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback